Novel approaches to the treatment of pneumonia

被引:9
作者
Cazzola, M
Matera, MG
Page, CP
机构
[1] Cardarelli Hosp, Dept Resp Med, Unit Pneumol & Allergol, I-80121 Naples, Italy
[2] Univ Naples 2, Dept Expt Med, Pharmacol Unit, Naples, Italy
[3] Kings Coll London, Sackler Inst Pulm Pharmacol, GKT Sch Biomed Sci, London WC2R 2LS, England
关键词
D O I
10.1016/S0165-6147(03)00129-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As the prevalence of resistance to multiple antibiotics increases it is progressively more difficult to treat pneumonia in hospitalized patients. Therefore, anti-infectious agents that have new modes of action are needed urgently. Recent advances in DNA sequencing technology make it possible to elucidate the sequences of the entire genomes of pathogenic bacteria. This allows many novel, non-traditional targets for therapeutic intervention to be identified, such as those involved in disease pathogenesis, and in adaptation and growth at sites of infection. In the past few years, inhibitors of new bacterial targets have been developed, including inhibitors of genes that are required for either virulence or pathogenesis. The challenge is to optimize and develop these agents to provide novel approaches to the treatment of pneumonia in hospitalized patients.
引用
收藏
页码:306 / 314
页数:9
相关论文
共 65 条
[1]   Bacterial lipopolysaccharides and innate immunity [J].
Alexander, C ;
Rietschel, ET .
JOURNAL OF ENDOTOXIN RESEARCH, 2001, 7 (03) :167-202
[2]   Virulence as a target for antimicrobial chemotherapy [J].
Alksne, LE .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (08) :1149-1159
[3]  
Barrett John F, 2001, Expert Opin Ther Targets, V5, P531, DOI 10.1517/14728222.5.4.531
[4]  
BAVINGTON C, IN PRESS BR J PHARM
[5]   A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia [J].
Bunnell, E ;
Lynn, M ;
Habet, K ;
Neumann, A ;
Perdomo, CA ;
Friedhoff, LT ;
Rogers, SL ;
Parrillo, JE .
CRITICAL CARE MEDICINE, 2000, 28 (08) :2713-2720
[6]   Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia [J].
Canny, G ;
Levy, O ;
Furuta, GT ;
Narravula-Alipati, S ;
Sisson, RB ;
Serhan, CN ;
Colgan, SP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (06) :3902-3907
[7]   Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections [J].
Cazzola, M ;
Blasi, F ;
Centanni, S ;
Donner, CF ;
Allegra, L .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2001, 14 (05) :367-381
[8]   Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense [J].
Chen, GH ;
Reddy, RC ;
Newstead, MW ;
Tateda, K ;
Kyasapura, BL ;
Standiford, TJ .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6496-6503
[9]   Carbohydroxamido-oxazolidines: Antibacterial agents that target lipid A biosynthesis [J].
Chen, MH ;
Steiner, MG ;
de Laszlo, SE ;
Patchett, AA ;
Anderson, MS ;
Hyland, SA ;
Onishi, HR ;
Silver, LL ;
Raetz, CRH .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (03) :313-318
[10]  
Chopra I, 1999, Expert Opin Investig Drugs, V8, P1203, DOI 10.1517/13543784.8.8.1203